Physiology and pharmacology of amyloid precursor protein
- PMID: 35114285
- DOI: 10.1016/j.pharmthera.2022.108122
Physiology and pharmacology of amyloid precursor protein
Erratum in
-
Corrigendum to "Physiology and pharmacology of amyloid precursor protein" [Pharmacology & Therapeutics Volume 235(2022) 108122.Pharmacol Ther. 2022 Oct;238:108281. doi: 10.1016/j.pharmthera.2022.108281. Epub 2022 Sep 20. Pharmacol Ther. 2022. PMID: 36137852 No abstract available.
Abstract
Amyloid precursor protein (APP) is an evolutionarily conserved transmembrane protein and a well-characterized precursor protein of amyloid-beta (Aβ) peptides, which accumulate in the brains of individuals with Alzheimer's disease (AD)-related pathologies. Aβ has been extensively investigated since the amyloid hypothesis in AD was proposed. Besides Aβ, previous studies on APP and its proteolytic cleavage products have suggested their diverse pathological and physiological functions. However, their roles still have not been thoroughly understood. In this review, we extensively discuss the evolutionarily-conserved biology of APP, including its structure and processing pathway, as well as recent findings on the physiological roles of APP and its fragments in the central nervous system and peripheral nervous system. We have also elaborated upon the current status of APP-targeted therapeutic approaches for AD treatment by discussing inhibitors of several proteases participating in APP processing, including α-, β-, and γ-secretases. Finally, we have highlighted the future perspectives pertaining to further research and the potential clinical role of APP.
Keywords: APP intracellular domain; Alzheimer’s disease; Amyloid precursor protein; Soluble APPα.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that there are no conflicts of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical